EU regulator approves injectable HIV drug that experts say could help stop transmission
Summary
A European drug agency has recommended approving a new injectable HIV prevention medicine called lenacapavir, produced by Gilead Sciences. This drug, which could prevent HIV transmission when administered twice a year, may soon be available across Europe and other regions if approved by the European Commission.Key Facts
- The European Medicines Agency advised authorizing lenacapavir, an injectable drug to prevent HIV.
- Lenacapavir is branded as Yeytuo in Europe.
- The drug stops HIV transmission and lasts six months per dose.
- Lenacapavir was approved by the U.S. Food and Drug Administration for HIV prevention.
- The World Health Organization suggested it as an additional prevention option.
- Lenacapavir provides longer-lasting protection compared to other treatments like daily pills.
- Gilead will allow cheaper generic versions in 120 countries with high HIV rates.
- Concerns exist about its limited availability in Latin America, where HIV rates are rising.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
